# Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

> **NCT04714697** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 201 (estimated)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Cabometyx

## Key facts

- **NCT ID:** NCT04714697
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 201 (ESTIMATED)
- **Last updated:** 2021-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04714697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04714697, "Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04714697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*